Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

170429

registered interest
date	15/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Drugs: Licensing
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 5 December 2014 to Question 216943, whether he plans to include issues related to off-patent drugs in the Innovative Medicines and MedTech Review.
tabling member constituency	Newcastle upon Tyne North
tabling member printed	Catherine McKinnell
uin	218729
answer	answer is ministerial correction date of answer 18/12/2014 answer text <p>The terms of reference of the Innovative Medicines and MedTech Review are still being developed. As set out in a Written Ministerial Statement on 20 November 2014, we expect this to focus on the most innovative medicines, devices and diagnostics which would include innovative use of existing medicine. Where appropriate this may cover off patent medicines, but final decisions on scope have not yet been taken. A link to the statement is provided:</p><p> </p><p> </p><p> </p><p><a href="http://www.parliament.uk/documents/commons-vote-office/November%202014/20%20November/2-Health-InnovativeMedicines.pdf" target="_blank">http://www.parliament.uk/documents/commons-vote-office/November%202014/20%20November/2-Health-InnovativeMedicines.pdf</a></p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 18/12/2014 17:35:55 answering member 4020 label Biography information for George Freeman
tabling member	4125 label Biography information for Catherine McKinnell

170430

registered interest
date	15/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Drugs: Licensing
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 5 December 2014 to Question 216943, whether the statement that off-patent drugs are widely used in the NHS refers to the use of off-patent drugs outside of their licensed indications.
tabling member constituency	Newcastle upon Tyne North
tabling member printed	Catherine McKinnell
uin	218728
answer	answer is ministerial correction date of answer 18/12/2014 answer text <p>Yes.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 18/12/2014 17:04:13 answering member 4020 label Biography information for George Freeman
tabling member	4125 label Biography information for Catherine McKinnell

170510

registered interest
date	15/12/2014
answering body	Ministry of Justice
answering dept id	54
answering dept short name	Justice
answering dept sort name	Justice
hansard heading	Ministry of Justice: Written Questions
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Justice, when he plans to answer Question 215901, tabled on 25 November 2014; and what the reasons are for the time taken to answer that Question.
tabling member constituency	Newcastle upon Tyne North
tabling member printed	Catherine McKinnell
uin	218674
answer	answer is ministerial correction date of answer 18/12/2014 answer text <p>I am sorry for the delay in answering Question 215901. I can confirm that the question has been answered today, 18<sup>th</sup> December 2014.</p> answering member constituency Hemel Hempstead answering member printed Mike Penning question first answered 18/12/2014 13:39:34 answering member 1528 label Biography information for Sir Mike Penning
tabling member	4125 label Biography information for Catherine McKinnell

168950

registered interest
date	09/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Parkinson's Disease: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 8 December 2014 to Question 216992, how many incidents of medication errors involving hospital patients with Parkinson's disease resulting in no harm were reported to the National Reporting and Learning System between July and November 2014; and which reporting organisation reported each such incident.
tabling member constituency	Newcastle upon Tyne North
tabling member printed	Catherine McKinnell
uin	217988
answer	answer is ministerial correction date of answer 15/12/2014 answer text <p>A table is attached showing the number of patient safety incidents involving Parkinson’s disease and medicines used to treat Parkinson’s disease, which resulted in ‘no harm’ that were reported to the National Reporting and Learning System between July and November 2014, together with the reporting organisation that reported each such incident.</p><p> </p><p> </p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 15/12/2014 16:58:54 answering member 3932 label Biography information for Dr Dan Poulter attachment 1 file name PQ217988 Table of Incidents.docx title Table of Incidents
tabling member	4125 label Biography information for Catherine McKinnell

168305

registered interest
date	05/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Neurology
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what progress his Department has made in implementing the recommendations of the Public Accounts Committe report, Services for people with neurological conditions, published on 16 March 2012; and if he will make a statement.
tabling member constituency	Newcastle upon Tyne North
tabling member printed	Catherine McKinnell
uin	217478
answer	answer is ministerial correction date of answer 10/12/2014 answer text <p>In July 2014, the Treasury published <em>Progress report on the implementation of Government accepted recommendations of the Committee of Public Accounts (PAC) - Sessions 2010­-12 and 2012-13</em>. It sets out progress against the four recommendations made by the PAC in its report <em>Services for people with neurological conditions,</em> with which the Department agreed. Two of the recommendations concerned the development of a neurological conditions dataset (recommendation two) and the neurological conditions quality standard (recommendation six) and they are now shown as being fully implemented.</p><p> </p><p> </p><p> </p><p>The changes introduced by the Health and Social Care Act 2012, means that the delivery of recommendations three and five, which concern the means to address certain service improvements and changes to the clinical commissioning group outcome indicator set, are no longer within the Department’s remit. The progress report sets out actions taken relevant to these areas and can be found at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://www.gov.uk/government/uploads/system/uploads/attachment_data/file/329001/9781474108553_WEB.PDF" target="_blank">www.gov.uk/government/uploads/system/uploads/attachment_data/file/329001/9781474108553_WEB.PDF</a>.</p><p> </p><p><strong> </strong></p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 10/12/2014 17:00:48 answering member 1439 label Biography information for Norman Lamb
tabling member	4125 label Biography information for Catherine McKinnell

167775

registered interest
date	03/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Parkinson's Disease: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many incidents involving Parkinson's disease and medicines used to treat Parkinson's disease resulting in (a) low, (b) moderate and (c) severe harm were reported to the National Reporting and Learning System between July and November 2014; and which reporting organisation reported each such incident.
tabling member constituency	Newcastle upon Tyne North
tabling member printed	Catherine McKinnell
uin	216992
answer	answer is ministerial correction date of answer 08/12/2014 answer text <p>A table is attached showing the number of patient safety incidents involving Parkinson’s disease and medicines used to treat Parkinson’s disease, which resulted in low harm, moderate harm and severe harm that were reported to the National Reporting and Learning System between July and November 2014, together with the reporting organisation that reported each such incident.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 08/12/2014 17:20:01 answering member 3932 label Biography information for Dr Dan Poulter attachment 1 file name Patient safety incidents- Parkinson's disease July-Nov 2014.docx title Patient safety incidents- Parkinson's Disease
tabling member	4125 label Biography information for Catherine McKinnell

167496

registered interest
date	02/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Drugs: Licensing
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the contribution by the Parliamentary Under Secretary of State for Health on the Off-patent Drugs Bill of 7 November 2014, columns 1114-1118, what discussions he has had with hospitals and GPs on changing clinical pathways to reflect the latest evidence to improve the uptake of effective off-patent drugs; what steps he has taken to set up a round-table discussion of these issues with NHS England and the National Institute for Health and Care Excellence (NICE); when this discussion will take place; and what steps he has taken to accelerate the uptake of (a) off-patent drugs and (b) innovative medicines through NICE guidance.
tabling member constituency	Newcastle upon Tyne North
tabling member printed	Catherine McKinnell
uin	216943
answer	answer is ministerial correction date of answer 05/12/2014 answer text <p>We have had no such discussions with hospital doctors and general practitioners. Clinicians can already prescribe off-patent drugs and these are widely used in the National Health Service but we are in the process of setting up a round-table discussion with key stakeholders, and are discussing suitable dates with them. Current prescribing arrangements allow clinicians to prescribe such drugs off-label and off-license when it best meets their patients individual clinical needs.</p><p> </p><p>The majority of significant new drugs are referred to the National Institute for Health and Care Excellence (NICE) technology appraisal work programme. NHS commissioners are required to fund drugs and treatments recommended by NICE technology appraisal guidance. Other NICE guidance, including clinical guidelines, may address the use of off-patent drugs for treating particular conditions and we expect clinicians and commissioners to take account of this guidance.</p><p> </p><p> </p><p> </p><p>The Government has recently launched an external review of the pathways for the development, assessment, and adoption of innovative medicines and medical technology to consider how to speed up access for NHS patients to cost-effective new diagnostics, medicines and devices.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 05/12/2014 13:09:58 answering member 4020 label Biography information for George Freeman
tabling member	4125 label Biography information for Catherine McKinnell

167535

registered interest
date	02/12/2014
answering body	Department for International Development
answering dept id	20
answering dept short name	International Development
answering dept sort name	International Development
hansard heading	International Climate Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for International Development, with reference to the intervention statement for the Climate Public Private Partnership (CP3) Platform, which private equity firm manages the Scottish Limited Partnership for the UK's investment in the CP3 Asia Fund through this Scottish Limited Partnership; and what the cost is of the fees charged by the Scottish Limited Partnership.
tabling member constituency	Newcastle upon Tyne North
tabling member printed	Catherine McKinnell
uin	216945
answer	answer is ministerial correction date of answer 05/12/2014 answer text <p>The UK’s investment into the CP3 Asia Fund, named ‘Asia Climate Partners’, is a Cayman Islands based Limited Partnership. The UK’s investment into the IFC Catalyst Fund is through a Scottish limited partnership. The tax jurisdiction is therefore in the Cayman Islands for Asia Climate Partners, and in Scotland for the Catalyst Fund. There are no fees charged by either limited partnership. These jurisdictions were chosen because they comply with the OECD Global Forum on Transparency and Exchange of Information for Tax Purposes.</p><p> </p><p>The IFC Catalyst Fund reached first close in November 2012 and the Asia Climate Partners reached first close in November 2014.</p><p> </p> answering member constituency New Forest West answering member printed Mr Desmond Swayne grouped question UIN 216944 216946 question first answered 05/12/2014 14:08:15 answering member 55 label Biography information for Sir Desmond Swayne
tabling member	4125 label Biography information for Catherine McKinnell

167536

registered interest
date	02/12/2014
answering body	Department for International Development
answering dept id	20
answering dept short name	International Development
answering dept sort name	International Development
hansard heading	International Climate Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for International Development, what the tax jurisdiction is for the Climate Public Private Partnership (CP3) Asia Fund and (b) International Finance Corporation Catalyst Fund.
tabling member constituency	Newcastle upon Tyne North
tabling member printed	Catherine McKinnell
uin	216946
answer	answer is ministerial correction date of answer 05/12/2014 answer text <p>The UK’s investment into the CP3 Asia Fund, named ‘Asia Climate Partners’, is a Cayman Islands based Limited Partnership. The UK’s investment into the IFC Catalyst Fund is through a Scottish limited partnership. The tax jurisdiction is therefore in the Cayman Islands for Asia Climate Partners, and in Scotland for the Catalyst Fund. There are no fees charged by either limited partnership. These jurisdictions were chosen because they comply with the OECD Global Forum on Transparency and Exchange of Information for Tax Purposes.</p><p> </p><p>The IFC Catalyst Fund reached first close in November 2012 and the Asia Climate Partners reached first close in November 2014.</p><p> </p> answering member constituency New Forest West answering member printed Mr Desmond Swayne grouped question UIN 216944 216945 question first answered 05/12/2014 14:08:15 answering member 55 label Biography information for Sir Desmond Swayne
tabling member	4125 label Biography information for Catherine McKinnell

167538

registered interest
date	02/12/2014
answering body	Department for International Development
answering dept id	20
answering dept short name	International Development
answering dept sort name	International Development
hansard heading	International Climate Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for International Development, with reference to intervention statement for the Climate Public Private Partnership (CP3) Platform, for what reason the UK's investment in the CP3 Asia Fund is made via a Scottish Limited Partnership.
tabling member constituency	Newcastle upon Tyne North
tabling member printed	Catherine McKinnell
uin	216944
answer	answer is ministerial correction date of answer 05/12/2014 answer text <p>The UK’s investment into the CP3 Asia Fund, named ‘Asia Climate Partners’, is a Cayman Islands based Limited Partnership. The UK’s investment into the IFC Catalyst Fund is through a Scottish limited partnership. The tax jurisdiction is therefore in the Cayman Islands for Asia Climate Partners, and in Scotland for the Catalyst Fund. There are no fees charged by either limited partnership. These jurisdictions were chosen because they comply with the OECD Global Forum on Transparency and Exchange of Information for Tax Purposes.</p><p> </p><p>The IFC Catalyst Fund reached first close in November 2012 and the Asia Climate Partners reached first close in November 2014.</p><p> </p> answering member constituency New Forest West answering member printed Mr Desmond Swayne grouped question UIN 216945 216946 question first answered 05/12/2014 14:08:15 answering member 55 label Biography information for Sir Desmond Swayne
tabling member	4125 label Biography information for Catherine McKinnell